无金标立体定向体部放疗中低可见度肿瘤的稳健定位
本研究开发了深度学习框架SAFE Track,用于无金标、无模板的肺部肿瘤定位,并在94例(415分次;40348帧)低肿瘤可见度患者中评估。SAFE Track在肿瘤>15 mm时三维距离误差为1.23±1.32 mm,在<10 mm时为1.82±1.67 mm,均优于Deep Match和XLT。SAFE Track是稳健、临床兼容、无金标且无模板的追踪框架,适用于SBRT中小肿瘤或被重叠解剖结构遮挡的肿瘤患者。
要点
- SAFE Track在肿瘤>15 mm时三维距离误差为1.23±1.32 mm,优于Deep Match(4.75±1.67 mm)和XLT(12.23±4.58 mm)。
- 在最具挑战的肿瘤<10 mm时,SAFE Track保持稳健,三维距离误差为1.82±1.67 mm,优于Deep Match(5.32±2.32 mm)和XLT(24.83±12.95 mm)。
- SAFE Track可检测肿瘤几乎不可见或与致密解剖结构重叠的极具挑战性病例。
核心结论
- SAFE Track是稳健、临床兼容、无金标且无模板的追踪框架,适用于SBRT中小肿瘤或被重叠解剖结构遮挡的肿瘤患者。
研究设计与样本
- SAFE Track为全监督框架,先在DeepLesion和Node21两个大型医学图像数据集上预训练,再在本院数据集上微调。
- 检测网络选用Faster R-CNN两阶段检测器,骨干网络为ResNet50。
- 纳入94例肿瘤可见度低并因此植入金标的患者(415分次;40348帧),按肿瘤最长径分为<10 mm、10-15 mm和>15 mm。
- 患者分为训练集(n=66)和测试集(n=28);仅在训练患者中模拟去除金标,测试使用金标植入肿瘤外的患者。
- 对比方法包括商用Xsight Lung Tracking(XLT)和Deep Match。
主要发现
- 在肿瘤>15 mm的测试患者中,SAFE Track三维距离误差为1.23±1.32 mm,Deep Match为4.75±1.67 mm,XLT为12.23±4.58 mm。
- 在肿瘤<10 mm的测试患者中,SAFE Track三维距离误差为1.82±1.67 mm,Deep Match为5.32±2.32 mm,XLT为24.83±12.95 mm。
- SAFE Track可检测肿瘤几乎不可见或与致密解剖结构重叠的极具挑战性病例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Effective respiratory motion management reduces healthy tissue toxicity and ensures sufficient dose delivery to lung cancer cells in pulmonary stereotactic body radiation therapy (SBRT) with high fractional doses. An articulated robotic arm paired with an X-ray imaging system is designed for real-time motion-tracking (RTMT) dose delivery. However, small tumors (<15 mm) or tumors at challenging locations may not be visible in the X-ray images, disqualifying patients with such tumors from RTMT dose delivery unless fiducials are implanted via an invasive procedure. To track these practically invisible lung tumors in SBRT, we hereby develop a deep learning-enabled template-free tracking framework, SAFE Track. METHODS: SAFE Track is a fully supervised framework that trains a generalizable prior for template-free target localization. Two sub-stages are incorporated in SAFE Track, including the initial pretraining on two large-scale medical image datasets (DeepLesion and Node21) followed by fine-tuning on our in-house dataset. A two-stage detector, Faster R-CNN, with a backbone of ResNet50, was selected as our detection network. 94 patients (415 fractions; 40,348 total frames) with low tumor visibility who thus had implanted fiducials were included. The cohort is categorized by the longest dimension of the tumor (<10 mm, 10-15 mm and > 15 mm). The patients were split into training (n = 66) and testing (n = 28) sets. We simulated fiducial-free tumors by removing the fiducials from the X-ray images. We classified the patients into two groups - fiducial implanted inside tumors and implanted outside tumors. To ensure the rigor of our experiment design, we only conducted fiducial removal simulation in training patients and utilized patients with fiducial implanted outside of the tumors for testing. Commercial Xsight Lung Tracking (XLT) and a Deep Match were included for comparison. RESULTS: SAFE Track achieves promising outcomes to as accurate as 1.23±1.32 mm 3D distance in testing patients with tumor size > 15 mm where Deep Match is at 4.75±1.67 mm and XLT is at 12.23±4.58 mm 3D distance. Even for the most challenging tumor size (<10 mm), SAFE Track maintains its robustness at 1.82 plus or minus 1.67 mm 3D distance, where Deep Match is at 5.32 plus or minus 2.32 mm, and XLT is at 24.83±12.95 mm 3D distance. Moreover, SAFE Track can detect some considerably challenging cases where the tumor is almost invisible or overlapped with dense anatomies. CONCLUSION: SAFE Track is a robust, clinically compatible, fiducial-free, and template-free tracking framework that is applicable to patients with small tumors or tumors obscured by overlapped anatomies in SBRT.
引用
- Xu D, Descovich M, Liu H, et al. Robust localization of poorly visible tumor in fiducial free stereotactic body radiation therapy. Radiother Oncol. 2024. PMID: 39214256. doi:10.1016/j.radonc.2024.110514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。